Research Article

Circulating MMP-12 as Potential Biomarker in Evaluating Disease Severity and Efficacy of Sublingual Immunotherapy in Allergic Rhinitis

Figure 5

Serum MMP-12 and MRGPRX2 levels in the effective and ineffective groups 3 years post-SLIT. (a–c) Serum MMP-12 levels were significantly lower in the effective group compared to the ineffective group, and concentrations were significantly decreased after 3 years of SLIT than pre-SLIT and post-SLIT 1 year. (d–f) Serum MRGPRX2 levels were lower in the effective group than the ineffective group, and the concentrations were also decreased 3 years post-SLIT, but no statistical difference was observed between 3 years and 1 year post-SLIT. MMP-12: matrix metalloproteinase-12; MRGPRX2: mas-related G protein-coupled receptor-X2; SLIT: sublingual immunotherapy, , , NS: no significance.
(a)
(b)
(c)
(d)
(e)
(f)